NPM1 and acute myeloid leukemia: Given the genetic etiology of AML [23,67,68] and the success of monitoring by PCR-MRD in acute promyelocytic and NPM1-mutated AMLs [40,69], there is growing interest in the detection and quantification of AML-associated mutations to estimate residual disease burden using NGS, either for predicting risk of relapse after transplant or for modulating transplant strategy (for example, conditioning regimens or post-transplant maintaining therapy).